Induction of early atherosclerosis in LDL-receptor-deficient mice immunized with β2-glycoprotein I

Circulation

Volumn 98, Issue 11, 1998, Pages 1108-1115

  George, Jacob ^a   Afek, Arnon ^a   Gilburd, Boris ^a   Blank, Miri ^a   Levy, Yair ^a   Aron Maor, Anabel ^a   Levkovitz, Hana ^a   Shaish, Aviv ^a   Goldberg, Iris ^a   Kopolovic, Juri ^a   Harats, Dror ^a   Shoenfeld, Yehuda ^a  

^a SHEBA MEDICAL CENTER   (Israel)

Author keywords

Antibodies; Atherosclerosis; Glycoproteins; Lipoproteins

Indexed keywords

BETA2 GLYCOPROTEIN 1; LOW DENSITY LIPOPROTEIN RECEPTOR;

ACTIVE IMMUNIZATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPHOSPHOLIPID SYNDROME; AORTA ATHEROSCLEROSIS; ARTICLE; ATHEROGENESIS; ATHEROSCLEROTIC PLAQUE; DISEASE ASSOCIATION; FEMALE; IMMUNOPATHOGENESIS; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0032530883     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.98.11.1108     Document Type: Article

References (48)

1. Hughes GRV. The antiphospholipid syndrome: ten years on. Lancet. 1993;342:341-344.
2. Hojnik M, George J, Ziporen L, Shoenfeld Y. Heart valve involvement (Libman-Sacks endocarditis) in the antiphospholipid syndrome. Circulation. 1996;93:1579-1587.
3. Tsakraklides VG, Blieden IC, Edwards JE. Coronary atherosclerosis and myocardial infarction associated with systemic lupus erythematosus. Am Heart J. 1974;87:637-641.
4. Jonsson H, Nived O, Sturfelt G. Outcome of systemic lupus erythematosus: a prospective study of patients from a defined population. Medicine (Baltimore). 1989;68:141-150.
5. Harris EN. Antiphospholipid antibodies. Br J Haematol. 1990;74:1-9.
6. Galli M, Comfurius M, Maassen C, Hemker HC, De Baets MH, van Breda-Vriesman PJ, Barbui T, Zwaal RF, Bevers EM. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet. 1990;335:1544-1547.
7. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Antiphospholipid antibodies are directed against a complex antigen that includes a lipid binding inhibitor of coagulation: β2GPI (apolipoprotein H). Proc Natl Acad Sci U S A. 1990;87:4120-4124.
8. Roubey RAS, Eisenberg RA, Harper MF, Winfield JB. "Anticardiolipin antibodies" recognize β2-glycoprotein in the absence of phospholipids: importance of antigen density and bivalent binding. J Immunol. 1995; 154:954-960.
9. Matsuura E, Igarashi Y, Fujimoto M, Ichikawa D, Suzuki T, Sumida T, Yasuda T, Koike T. Heterogeneity of anticardiolipin antibodies defined by the anticardiolipin cofactor. J Immunol. 1992;148:3885-3891.
10. Kandia DA, Krilis SA. Beta2-glycoprotein I. Lupus. 1994;3:207-212.
11. Tsutsumi A, Matsuura E, Ichikawa K, Fujisaku A, Mukai M, Kobayashi S, Koike T. Antibodies to β2GPI and clinical manifestations in patients with systemic lupus erythematosus. Arthritis Rheum. 1996;39:1466-1474.
12. Alarcon-Segovia D, Cabral AR. The antiphospholipid/cofactor syndromes. J Rheumatol. 1996;23:1319-1322.
13. Gharavi AE, Sammaritano LR, Wen J, Elkon KB. Induction of antiphospholipid antibodies by immunization with β2 glycoprotein I (apolipoprotein H). J Clin Invest. 1992;90:1105-1109.
14. Pierangeli SS, Harris EM. Induction of phospholipid binding antibodies in mice and rabbits by immunization with human beta 2 glycoprotein 1 or anticardiolipin antibodies alone. Clin Exp Immunol. 1993;93:269-272.
15. Kouts S, Wang MX, Adelstein S, Krilis SA. Immunization of a rabbit with β2-glycoprotein I induces charge dependent cross-reactive antibodies that bind phospholipids and have similar reactivity as autoimmune antiphospholipid antibodies. J Immunol. 1995;155:958-966.
16. Blank M, Faden D, Tincani A, Kopolovic J, Goldberg I, Gilburd B, Allegri F, Balestrieri G, Valesini G, Shoenfeld Y. Immunization with anticardiolipin cofactor (beta-2 glycoprotein-I) induces antiphospholipid syndrome in naive mice. J Autoimmunity. 1994;7:441-455.
17. Garcia C, Kanbour Shakir A, Tang H, Espinoza LR, Gharavi AE. Induction of experimental antiphospholipid syndrome in PL/J mice following immunization with beta 2 glycoprotein I. Am J Repr Immunol. 1997;37:118-129.
18. Aron AL, Cuellar RL, Brey RL, Meceown S, Espinoza LR, Shoenfeld Y, Gharavi AE. Early onset of autoimmunity in MRL/++ mice following immunization with beta 2 glycoprotein I. Clin Exp Immunol. 1995;101: 78-84.
19. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801-809.
20. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol: modification of low-density lipoprotein that increase its atherogenicity. N Engl J Med. 1989;320:915-924.
21. Witztum JL. The oxidation hypothesis of atherosclerosis. Lancet. 1994; 344:793-795.
22. Vaarala O, Alfthan G, Jauhiainen M, Leirisalo-Repo M, Aho K, Palosuo T. Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet. 1993;923-925:.
23. Mizutani H, Kurata Y, Kosugi S, Shiraga M, Kashiwagi H, Tomiyama Y, Kanakura Y, Good RA, Matsuzawa Y. Monoclonal anticardiolipin autoantibodies established from the (New Zealand White x BXSB)F1 mouse model for antiphospholipid syndrome cross-react with oxidized low-density lipoprotein. Arthritis Rheum. 1995;38:1382-1388.
24. Vaarala O, Puurunen M, Lukka M, Alfthan G, Leirisalo-Repo M, Aho K, Palosuo T. Affinity purified cardiolipin binding antibodies show heterogeneity in their binding to oxidized low density lipoprotein. Clin Exp Immunol. 1996;104:269-274.
25. Horkko S, Miller E, Dudl E, Reaven P, Curtiss LK, Zvaifler NJ, Terkeltaub R, Pierangeli SS, Branch DW, Palinski W, Witztum JL. Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids. J Clin Invest. 1996;98:815-825.
26. Hasunuma Y, Matsuura E, Makita Z, Katahira T, Nishi S, Koike T. Involvement of β2 glycoprotein I and anticardiolipin antibodies in oxidatively modified low density lipoprotein uptake by macrophages. Clin Exp Immunol. 1997;107:569-574.
27. Simantov R, LaSala JM, Lo SK, Gharavi AE, Sammaritano LR, Salmon JE, Silverstein RL. Activation of cultured endothelial cells by antiphospholipid antibodies. J Clin Invest. 1995;96:2211-2219.
28. George J, Blank M, Levy Y, Meroni PL, Damianovich M, Tincani A, Shoenfeld Y. Differential effects of anti-β2GPI antibodies on endothelial cells and on the manifestations of experimental antiphospholipid syndrome. Circulation. 1998;97:900-906.
29. Ishibashi S, Brown MS, Goldstein JL, Gerard RD, Hammer RE, Herz J. Hypercholesterolemia in LDL receptor knockout mice and its reversal by adenovirus mediated gene delivery. J Clin Invest. 1993;92:883-893.
30. George J, Blank M, Hojnik M, Bar-Meir E, Koike T, Matsuura E, Lorber M, Aviram M, Shoenfeld Y. Oxidized low density lipoprotein (Ox-LDL) but not LDL aggravates the manifestations of experimental antiphospholipid syndrome. Clin Exp Immunol. 1997;108:227-233.
31. Igarashi M, Matsuura E, Igarashi Y, Nague H, Ichikawa K, Triplett DA, Koike T. Human β2-glycoprotein I as an anticardiolipin cofactor determined using delegated mutants expressed by abaculovirus system. Blood. 1996;87:3262-3270.
32. Nezlin R. Detection of the C3a complement component in commercial gamma globulins by dot blotting. J Immunol Methods. 1993;163:269-272.
33. Xu Q, Dietrich H, Steiner HJ, Gown AM, Schoel B, Mikuz B, Kaufman SHE, Wick G. Induction of arteriosclerosis in normocholesterolemic rabbits by immunization with heat shock protein 65. Arterioscler Thromb. 1992;12:789-799.
34. Salonen JT, Yla-Herttuala S, Yamamoto R, Butler S, Korpela H, Salonen R, Nyyssonen K, Paliniski W, Witztum JL. Antibodies against oxidized LDL and the progression of carotid atherosclerosis. Lancet. 1992;339:883-887.
35. Elias D, Markovits D, Reshef T, van der Zee R, Cohen IR. Induction and therapy in non-obese diabetic (NOD/Lt) mouse by a 65-kDa heat shock protein. Proc Natl Acad Sci U S A. 1990;87:1576-1580.
36. Paigen B, Morrow A, Holmes PA, Mitchell D, Williams RA. Quantitative assessment of atherosclerotic lesions in mice. Atherosclerosis. 1987;68: 231-240.
37. Rubin EM, Krauss RM, Spangler EA, Verstuyft JG, Clift SM. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein A-I. Nature. 1991;353:265-267.
38. Qiao JH, Xie PZ, Fishbein MC, Kreuzer J, Drake TA, Demer LL, Lusis AJ. Pathology of atheromatous lesions in inbred and genetically engineered mice: genetic determinations of arterial calcification. Arterioscler Thromb. 1994;14:1480-1497.
39. Wick G, Schett G, Amberger A, Kleindienst R, Xu Q. Is atherosclerosis an immunologically mediated disease? Immunol Today. 1995;16:27-33.
40. Libby P, Hansson GK. Involvement of the immune system in human atherogenesis: current knowledge and unanswered questions. Lab Invest. 1991;64:5-11.
41. Roselaar SE, Kakkanthu PX, Daughterly A. Lymphocyte population in atherosclerosis lesions of apoE -/- and LDL receptor -/- mice: decreasing density widi disease progression. Arterioscler Thromb Vasc Biol. 1996;16:1013-1018.
42. Palinski W, Miller E, Witztum JL. Immunization of low density lipoprotein (LDL) deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc Natl Acad Sci U S A. 1995; 92:821-825.
43. Ameli SA, Hultgardh-Nilsson A, Regnstrom J, Calara F, Yana J, Cercek B, Shah PK, Nilsson J. Effect of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits. Arterioscler Thromb Vasc Biol. 1996;16:1074-1079.
44. Hashimoto Y, Kawamura M, Ichikawa K, Suzuki T, Sumida T, Yoshida S, Matsuura E, Ikehara S, Koike T. Anticardiolipin antibodies in NZWxBXSB Fl mice: a model of antiphospholipid syndrome. J Immunol. 1992;149:1063-1068.
45. Hojnik M, Gilburd B, Ziporen L, Blank M, Tomer Y, Scheinberg MA, Tincani A, Rosman B, Shoenfeld Y. Anticardiolipin antibodies in infections are heterogenous in their dependency in β2 glycoprotein I: analysis of anticardiolipin in leprosy. Lupus. 1994;3:515-520.
46. Louizou S, Cazabon JK, Walport MJ, Tait D, So AK. Similarities of specificity and cofactor dependence in serum antiphospholipid antibodies from patients with human parvovirus B19 infection and from those with systemic lupus erythematosus. Arthritis Rheum. 1997;40:103-109.
47. Cook PJ, Lip GYH. Infectious agents and atherosclerotic vascular disease. Q J Med. 1996;89:727-735.
48. Libby P, Egan D, Scarlatos S. Roles of infectious agents in atherosclerosis and restenosis: an assessment of the evidence and need for future research. Circulation. 1997;96:4095-4103.